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Knowledge regarding the rate of central nervous system (CNS) involvement and risk factors for its devel-
opment in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation
(HCT) are limited. In this study we retrospectively evaluated CNS involvement in 327 patients who underwent
myeloablative HCT at our institute in which all patients have cerebrospinal ﬂuid examined by morphology or
ﬂow cytometry before HCT. Twenty-two patients (7%) had CNS AML involvement at pre-HCT evaluation.
Covariates associated with such involvement were higher WBC at diagnosis, prior CNS or other extra-
medullary disease, and evidence of systemic disease at pre-HCT evaluation. History of prior CNS disease and
disease status at pre-HCT evaluation allowed stratiﬁcation of patients into 3 risk groups: 35% (20 patients),
16% (51 patients), and 3% (256 patients) rates of pre-HCT CNS involvement. Treatment of pre-HCT CNS disease
was uniformly successful regardless of whether cranial irradiation therapy was used. Perhaps as a result,
presence of CNS pre-HCT had no independent inﬂuence on post-HCT outcome, which was primarily inﬂu-
enced by status of systemic disease at time of HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The exact incidence of central nervous system (CNS)
involvement in adults with acute myeloid leukemia (AML)
is unknown but is considered uncommon (<5%) [1-3].
Therefore, cerebrospinal ﬂuid (CSF) evaluation is usually
performed only in patients with neurological symptoms and,
unlike in acute lymphoblastic leukemia, prophylactic therapy
is not indicated [4]. Risk factors associated with CNS AML are
higher pretreatment levels of lactate dehydrogenase and
WBCs, chromosome 16 inversion and chromosome 11
abnormalities, FAB subgroup M4 and M5, and younger age
[5,6]. Although high-dose cytarabine, intrathecal chemo-
therapy, and cranial irradiation are effective treatments,
relapse rate is high and CNS involvement considered to be a
poor prognostic factor [2,7-9].
Allogeneic hematopoietic cell transplantation (HCT) can
be curative in AML [10,11]. However, despite advances inedgments on page 551.
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ty for Blood and Marrow Transplantation.therapy, relapse remains the major cause of post-HCT mor-
tality [12,13]. The incidence of CNS disease before and after
transplant and the effect of CNS disease on transplant
outcome is uncertain [3]. At our institution all AML patients
considered candidates for allogeneic HCT undergo routine
CSF examination as part of a pretransplant evaluation,
allowing a relatively unbiased look at the incidence of AML in
CSF pre-HCT. Therefore, the primary objectives of this study
were to assess the rate of CNS involvement in AML patients
undergoing HCT, evaluate potential risk factors for CNS
disease, and examine the effect of CNS involvement on
transplant outcome.
METHODS
Patient Population
We retrospectively evaluated 327 adults (age 18 years) with AML who
underwent myeloablative HCT at the Fred Hutchinson Cancer Research
Center between January 2007 and December 2012. Per standard practice at
our institution, all patients underwent routine evaluation for CNS AML
involvement at the time of pre-HCT evaluation by morphological or multi-
parameter ﬂow cytometric evaluation of cytospun CSF. AML CNS involve-
ment was deﬁned as unequivocal morphological or immunophenotypic
evidence of leukemic blasts in the CSF or in symptomatic patients by
abnormal ﬁndings on computed tomography or magnetic resonance
imaging.
Table 1
Patient Characteristics
Characteristic No CNS
Involvement
at Pre-HCT
Evaluation
(n ¼ 305)
CNS
Involvement
at Pre-HCT
Evaluation
(n ¼ 22)
P
Median age at HCT, yr (range) 49 (19-73) 50 (22-69) .49
Gender .66
Male 160 (52) 19 (45)
Female 145 (48) 12 (55)
Median WBC
count at diagnosis, 103/mL
(range)
5 (0-800) 34 (2-269) <.001
Risk group* .15
Unfavorable 79 (26) 5 (23)
Favorable 23 (8) 5 (23)
Intermediate-I 128 (42) 7 (32)
Intermediate-II 75 (25) 5 (23)
Prior CNS involvement <.001
Yes 13 (4) 7 (32)
No 290 (96) 15 (68)
Prior EMD (no CNS) .04
Yes 25 (8) 5 (23)
No 280 (92) 17 (77)
Prior HDAC treatment 1.0
Yes 195 (64) 14 (67)
No 108 (36) 7 (33)
Disease status at
pre-HCT evaluation
.0015
CR no MRD 163 (53) 4 (18)
CRp/CRi 38 (12) 3 (14)
CR-MRD 60 (20) 5 (23)
No CR 44 (14) 10 (45)
CR status at
pre-HCT evaluation
CR1 185 (61) 3 (14)
CR2 70 (23) 4 (18)
CR  3 6 (2) 5 (23)
No CR 44 (14) 10 (45)
HCT allotype .23
HLA
matched-related
102 (33) 10 (45)
HLA matched-unrelated 118 (39) 7 (32)
HLA mismatched-related 8 (3) 2 (9)
HLA mismatched-unrelated 55 (18) 3 (14)
Graft source .19
Bone marrow 58 (19) 8 (36)
Peripheral blood 208 (68) 13 (59)
Cord blood 38 (12) 1 (5)
HDAC indicates histone deacetylase.
Values are number of cases with percents in parentheses, unless otherwise
noted.
* Based on European LeukemiaNet risk classiﬁcation [4,20].
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Figure 1. Prior CNS and EMD among 327 AML patients undergoing myeloa-
blative HCT.
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were treated by intrathecal/intraventricular chemotherapy (cranial irra-
diation) and entered transplant with no evidence of CNS disease. Transplant
conditioning regimens included busulfan/cyclophosphamide (n ¼ 84),
treosulfan/ﬂudarabine/ low-dose total body irradiation (TBI) (n ¼ 79),
busulfan/ﬂudarabine (n ¼ 54), cyclophosphamide/high-dose TBI (n ¼ 37),
ﬂudarabine/I131 anti-CD45 Ab/ cyclophosphamide (n ¼ 35),
cyclophosphamide/ﬂudarabine/high-dose TBI (n ¼ 33), and others (n ¼ 5).
All patients provided informed consent for treatment approved by the
institutional review board. Separate institutional approval was obtained to
gather data from patient records and databases for this retrospective study.CSF Evaluation
Cytomorphological evidence of CNS involvement was deﬁned by
microscopic counting of myeloblasts in cytospun CSF preparations stained
with May-Grunwald-Giemsa. Cytomorphological analysis performed on
cytospun preparations is highly speciﬁc (>95%) but has a lower sensitivity of
approximately 80% [14]. In most cases CSF was also evaluated by multi-
parametric ﬂow cytometry, which has a diagnostic value more than twice
that of cytomorphology [15]. Flow cytometry analysis was performed on amodiﬁed 4-laser, 10-color Becton Dickinson LSRII ﬂow cytometer (BD Bio-
sciences, San Jose, CA) as previously described [16].
Statistical Methods
Wilcoxon rank sum tests were used to compare quantitative variables,
and Fisher’s exact test was used to compare categorical variables in patients
with and without CNS involvement. Overall survival (OS) after transplant
was measured from date of transplant to date of death due to any cause,
with patients last known to be alive censored at the date of last contact.
Relapse-free survival (RFS) after transplant was measured from the date of
transplant to the date of ﬁrst relapse or death from any cause, with patients
last known to be alive in complete remission (CR) censored at the date of last
contact. Time to relapse after transplant was measured from date of trans-
plant to date of relapses, with deaths in CR considered a competing event.
OS and RFS were estimated with the Kaplan-Meier method, and time to
relapse was estimated using cumulative incidence curves. Cox regression
models were used to assess OS and RFS, and proportional hazardsmodels for
the subdistribution of a competing risk were used to assess time to relapse.
Multivariable analyses for CNS involvement at time of transplant included
history of CNS involvement and other extramedullary disease (EMD),
remission status, cytogenetics, prior high-dose cytarabine (500 mg/m2 per
dose), and the quantitative covariatesWBC count and age. Classiﬁcation and
regression tree analysis was used to deﬁne subgroups at differing risk of CNS
disease at time of HCT.
RESULTS
Patient Characteristics
We retrospectively evaluated 327 adults with AML who
underwent myeloablative HCT. Median age was 49 years
(range, 19 to 73). Twenty-eight patients (9%) had favorable
karyotype (SWOG criteria), 215 (66%) had intermediate-risk
karyotype, and 84 (26%) had unfavorable karyotype at
diagnosis; 209 patients had received high-dose cytarabine.
At time of CNS evaluation pre-HCT, 167 patients were in CR
without minimal residual disease (MRD), 65 had CR with
MRD, 41 had CR with incomplete platelet recovery (CRp) or
CR with incomplete blood count recovery (CRi), and 54 had
overt systemic relapse (>5% blasts in marrow). Twenty pa-
tients had a prior history of CNS disease. Median follow-up
time among patients censored for OS was 3.1 years (1130
days). Characteristics of patients are presented in Table 1.
Predictors of CNS Relapse
Thirty-ﬁve patients (11%) had AML CNS involvement at
any time pre-HCT; among them, 22 (7%) had CNS AML
Table 2
CNS-Directed Therapy for 22 Patients with CNS Disease at Pre-HCT
Evaluation
Patient Intrathecal Therapy Cranial
Irradiation
(cGy)
Spinal
Irradiation
(cGy)
1 IT methotrexate (6); CSF cleared
after 2 doses
2400 1800
2 IT methotrexate (2); CSF cleared
after 1 dose
1800 1260
3 IT methotrexate (2); CSF cleared
after 1 dose
2200 None
4 IT methotrexate (4); CSF cleared
after 3 doses
2340 1800
5 IT methotrexate (3); CSF cleared
after 3 doses
2400 2400
6 IT methotrexate (3); CSF cleared
after 1 dose
2400 2400
7 IT methotrexate (5); CSF cleared
after 4 doses
2400 2400
8 IT methotrexate and cytarabine
(3); CSF cleared after 2 doses
2400 2400
9 IT methotrexate (5); CSF cleared
after 4 doses
2400 1800
10 IT methotrexate (2); CSF cleared
after 1 dose
None None
11 IT methotrexate (3); CSF cleared
after 2 doses
2400 2400
12 IT methotrexate and cytarabine
(3); CSF cleared after 2 doses
None None
13 IT methotrexate (4); CSF cleared
after 3 doses
1080 1080
14 IT methotrexate (2); CSF cleared
after 1 dose
None None
15 IT methotrexate (3); CSF cleared
after 2 doses
None None
16 IT methotrexate and cytarabine
(3); CSF cleared after 1 dose
None None
17 IT methotrexate (4); CSF cleared
after 3 doses
None None
18 IT methotrexate (3); CSF cleared
after 3 doses
None None
19 IT methotrexate (3); CSF cleared
after 2 doses
None None
20 IT methotrexate (2); CSF cleared
after 2 doses
1200 1200
21 IT methotrexate (4; clearer
after 3)
None None
22 Intraventricular (via Ommaya
reservoir) methotrexate (5)
followed by cytarabine (4); CSF
cleared after 5 methotrexate doses
None None
IT indicates intrathecal.
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patients had prior (treated) CNS AML, 3 had prior EMD not
involving the CNS, and 2 had both prior CNS and other EMD
(Figure 1). The incidence of CNS AML at pre-HCT evaluation
was 7 of 20 patients (35%) with past CNS involvement versus
15 in 305 patients (5%) without a history of CNS disease (P <
.001) and was 5 of 30 patients (17%) with a history of other
EMD versus 17 of 297 patients (6%) (P ¼ .04) with no prior
EMD.
Other covariates associated with CNS AML at pre-HCT
evaluation were higher WBC counts at diagnosis (P < .001,
medians of 34,000 in those with versus 5000 in those
without CNS disease) and disease status at time of CNS
evaluation pre-HCT (P < .001) with only 2% of patients in CR
without MRD having CNS involvement versus 9% of those
with CR with MRD, 7% of those with CRp or CRi, and 19% of
those with overt relapse. Age, karyotype, and receipt of high-
dose cytarabine were not associated with CNS involvement
pre-HCT in univariate analysis (Table 1).Seven of the 22 patients with CNS involvement at pre-
HCT evaluation had normal karyotype. Of these 22 patients,
7 patients had molecular studies performed; among them, 1
patient had FLT3 ITD mutation and 1 patient had FLT3 ITD
mutation and NPM1mutation (both with normal karyotype).
Among the 13 patients who had CNS involvement before
arrival to transplant but with negative CNS on pre-HCT
evaluation, 3 had normal karyotype. Six of those patients
had molecular studies performed, and all were negative.
Among the 35 patients with CNS disease at any time before
transplant, 7 had normal karyotype.
Classiﬁcation and regression tree analysis identiﬁed 3 risk
groups for pre-HCT CNS disease: (1) high, deﬁned as prior
CNS disease (20 patients, 35% with CNS involvement at pre-
HCT evaluation); (2) intermediate, deﬁned as no prior CNS
involvement but with systemic relapse at time of pre-HCT
evaluation (51 patients, 16% with CSF involvement at pre-
HCT evaluation); and (3) low, deﬁned as no prior CNS dis-
ease and systemic CR at time of pre-HCT evaluation (256
patients, 3% with CSF involvement).
No routine imaging was performed for evaluation of AML
CNS disease, but brain or spine imaging was performed if
patients presented with neurological or other concerning
symptoms, independent of CSF involvement. Nine of the 22
patients found to have positive CSF disease during pre-HCT
evaluation underwent brain or spine imaging. Abnormal-
ities were identiﬁed in 2 cases: Thoracic spine chloroma was
identiﬁed in a patient presenting with paresthesia and left
temporal chloroma was identiﬁed in a patient presenting
with headache and diplopia. In both cases, patients were also
found to have abnormal blasts in CSF evaluation.
An additional 50 patients arrived on the transplant ser-
vice during this period of time but did not undergo trans-
plant, primarily because of refractory disease. Of these 50
patients, 33 underwent lumbar puncture as part of the pre-
HCT evaluation, and 7 patients (21%) were found to have
CNS disease. Six of these 7 patients had concurrent marrow
involvement. Two of the 50 patients had evidence of CNS
involvement before arrival for pretransplant evaluation;
however, most patients did not have CNS evaluation before
arrival to transplant.Effect of Pretransplant CNS Involvement on Post-
Transplant CNS Involvement and Transplant Outcome
All 22 patients with CNS involvement at pre-HCT evalu-
ation received CNS-directed treatment with intrathecal
methotrexate (usually) or cytarabine. The median number of
intrathecal therapies was 3 (range, 2 to 9), with clearance of
CSF after a median of 2 doses (range, 1 to 5). Twelve patients
also received craniospinal irradiation with a median cranial
dose of 2400 cGy and a median spinal dose of 1800 cGy in
fractions of 200 cGy (Table 2). Eighteen patients also received
CNS-directed therapy after HCT (between 1 and 6 intrathecal
treatments). Nine and 8 patients with a prior history of CNS
disease but with no evidence of CNS involvement at time of
pre-HCT evaluation received CNS-directed therapy before
and after transplant, respectively. Eight of the 35 patients
with history of CNS disease pre-HCT received high-dose TBI
as part of their transplant conditioning, and 9 patients
received cranial irradiation. Two of the 35 patients (6%) with
CNS disease at any time pre-HCT had documented CNS dis-
ease after transplant. Patients with no evidence of CNS dis-
ease before HCT did not receive CNS prophylactic therapy
before or after transplant.
Table 3
Multivariate Analysis for OS after Transplant
Covariate Hazard
Ratio
95%
Conﬁdence
Interval
P
CNS disease at time pre-HCT
evaluation (ref ¼ no CNS disease)
1.35 (.32-5.8) .68
Prior CNS (ref ¼ no prior CNS) 1.23 (.59-2.54) .58
CR-MRD at time of HCT
(ref ¼ CR no MRD)
3.77 (2.4-5.92) <.001
CRp/CRi (ref ¼ CR no MRD) 1.49 (.81-2.74) .19
No CR (ref ¼ CR no MRD) 3.74 (2.32-6.03) <.001
WBC count at time of diagnosis 1 (1-1) .54
Favorable cytogenetics
(ref ¼ unfavorable)
.67 (.32-1.4) .28
Intermediate-I cytogenetics
(ref ¼ unfavorable)
.99 (.65-1.5) .96
Intermediate-II cytogenetics
(ref ¼ unfavorable)
.73 (.45-1.17) .19
EMD (ref ¼ no EMD) 1.22 (.67-2.2) .52
Age, yr 1 (.99-1.02) .9
Prior HDAC (ref ¼ no prior HDAC) 1.19 (.81-1.74) .37
CNS  CR-MRD (ref ¼ no CNS
and CR no MRD)
.74 (.12-4.55) .74
CNS  CRp/CRi (ref ¼ no CNS
and CR no MRD)
2.55 (.31-20.67) .38
CNS  no CR (ref ¼ no CNS
and CR no MRD)
1.22 (.22-6.64) .82
Table 4
Multivariate Analysis for RFS after Transplant
Covariate Hazard
Ratio
95%
Conﬁdence
Interval
P
CNS disease at time of pre-HCT
evaluation (ref ¼ no CNS disease)
1.38 (.33-5.89) .66
Prior CNS (ref ¼ no prior CNS) 1.16 (.59-2.31) .66
CR-MRD (ref ¼ CR no MRD) 4.49 (2.93-6.89) <.001
CRp/CRi (ref ¼ CR no MRD) 1.59 (.9-2.81) .11
No CR (ref ¼ CR no MRD) 4.32 (2.72-6.84) <.001
WBC count at time of diagnosis 1 (1-1) .14
Favorable cytogenetics
(ref ¼ unfavorable)
.82 (.41-1.63) .57
Intermediate-I cytogenetics
(ref ¼ unfavorable)
1 (.67-1.49) .99
Intermediate-II cytogenetics
(ref ¼ unfavorable)
.69 (.44-1.09) .11
EMD (ref ¼ no EMD) 1.48 (.87-2.53) .15
Age, yr 1 (.99-1.01) .76
Prior HDAC (ref ¼ no prior HDAC) 1.05 (.73-1.5) .8
CNS  CR-MRD (ref ¼ no
CNS and CR no MRD)
.47 (.08-2.88) .42
CNS  CRp/CRi (ref ¼ no
CNS and CR no MRD)
1.75 (.22-13.9) .6
CNS  No CR (ref ¼ no
CNS and CR no MRD)
.89 (.16-4.76) .89
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pre-HCT evaluation had shorter post-HCT OS (P ¼ .002).
However, multivariable analysis indicated that this reﬂected
the association of CNS diseasewith poorer systemic response
to pretransplant therapy and evidence of systemic disease at
time of transplant. Speciﬁcally, themultivariable hazard ratio
was 1.48 for CNS involvement versus no CNS involvement
(P ¼ .17) in contrast with a hazard ratio of 3.62 for CR with
MRD versus CR without MRD (P < .001) and 3.78 for no CR
versus CR without MRD (P < .001). Tests for interactions
indicated that the relatively small effect of CNS disease on
survival was similar in patients with CR þ MRD, CRp or CRi,
or neither CR nor CRp/CRi (Table 3). Similar results were
shown for RFS (Table 4). High-dose TBI or cranial irradiation
as part of the transplant conditioning regimen did not affect
time to relapse, RFS, and OS of the 35 patients with history of
CNS disease pre-HCT (Figure 2).DISCUSSION
CNS involvement is considered rare in adults with AML.
Therefore, in contrast to acute lymphoblastic leukemia
where CSF is routinely evaluated at diagnosis, in AML CSF is
typically examined only in patients with CNS symptoms. At
our institution, all AML patients considered candidates for
allogeneic HCT undergo routine CSF examination as part of a
pretransplant evaluation, allowing a relatively unbiased look
at the incidence of AML in CNS pre-HCT. Our retrospective
analysis of 327 patients revealed an 11% rate of CNS
involvement at any time prior to HCT. This rate is higher than
historically appreciated [1] but lower than the 19% AML CNS
involvement recently reported in newly diagnosed AML pa-
tients who underwent routine CSF evaluation [17]. A po-
tential explanation for the lower rate of CNS disease detected
in our cohort compared with the rate detected by Rozovski
et al. [17] is the differences in the patient population
included of these 2 studies. For example, Rozovski et al.
found that CNS involvement was more common in young
patients and among African-American patients. Our cohortincluded older patients (median age 49 versus 41 years) and
a lower rate of African-Americans (1.5% versus 8%), which
could affect the rate of CNS disease detected in these 2
studies. Another explanation could be a selection bias among
the 42 patients included in the investigational study re-
ported by Rozovski et al., whereas our study included all 327
patients who underwent HCT at our center.
By using a history of prior CNS disease and systemic
disease status at the time of pre-HCT evaluation, we identi-
ﬁed 3 risk groups for CNS involvement at the time of pre-HCT
evaluation. Although the rate of CNS involvement in the low-
risk group (no prior history of CNS disease and no evidence of
systemic disease at time of transplant) was lower compared
with the high-risk group (3% versus 35%), the low rate of
complications after lumbar puncture leads us to recommend
diagnostic lumbar puncture for all AML patients pre-HCT.
This approach is supported by the availability of effective
strategies to control CNS disease, as demonstrated by
clearing of CNS disease before HCT in all patients with CNS
disease in our cohort, with documentation of CNS disease
post-transplant in only 2 of the 35 patients (6%) with docu-
mented CNS disease at any time pre-HCT.
Thompson et al. [18] retrospectively evaluated the risk of
CNS relapse and leukoencephalopathy in patients who
received bone marrow transplant for ALL (n ¼ 198) and AML
(n¼ 217). Similar to our ﬁndings, they reported a small risk of
CNS AML relapse after transplant, with only 3 patients (all
transplanted in marrow relapse) developing CNS AML relapse
after transplant and with no clear association between CNS
disease pre-HCT and CNS relapse post-HCT. In addition to
supporting the ﬁndings of Thompson et al. in a more recent
and larger cohort, our study also demonstrated that high-dose
TBI or cranial irradiation as part of the transplant conditioning
regimen did not affect time to relapse, RFS, and OS of patients
with history of CNS disease pre-HCT. Additionally, our study
found risk factors for CNS disease pre-HCT, including prior
history CNS or other EMD, high WBC counts at diagnosis, and
systemic relapse at time of transplant.
CNS toxicity post-transplant was beyond of the scope of
our study. However, others have reported risk of
Figure 2. Transplant outcome of 35 patients with a history of AML CNS involvement before HCT, stratiﬁed by TBI dose (left) and cranial irradiation (right). (A) OS, (B)
RFS, (C) Cumulative incidence of relapse.
M. Bar et al. / Biol Blood Marrow Transplant 21 (2015) 546e551550leukoencephalopathy post-transplant when pre- and post-
HCT CNS-directed therapy was applied: Thompson et al.
[18] reported a 3% risk in AML adult patients, and Johnson
et al. [19] reported a 17% risk in acute lymphoblastic leuke-
mia pediatric patients who received pretransplant CNSprophylaxis and at least 6 doses of intrathecal methotrexate
post-transplant. Based on the relatively low risk of CNS AML
relapse post-HCT shown in our and Thompson et al.’s studies
and the potential risk for CNS toxicity with CNS-directed
therapy, no prophylactic CNS therapy is recommended for
M. Bar et al. / Biol Blood Marrow Transplant 21 (2015) 546e551 551AML patients undergoing HCT. However, because our ﬁnding
of no association between CNS disease pretransplant and
post-transplant survival is based on a population of patients
who cleared their CNS disease pre-HCT, our recommendation
is to treat and clear CNS disease before transplant. Similar to
our ﬁndings, Aoki et al. [3] recently demonstrated that AML
CNS disease is not an independent factor in determining
survival after HCT. Because all patients in our cohort had
cleared their CNS disease pretransplant, we were unable to
evaluate the effect of untreated CNS disease on transplant
outcome. However, our results indicate that CNS AML is
associated with unsuccessfully treated systemic AML, which
by itself is associated with poor outcome after HCT.
This study has several limitations. The data were collected
retrospectively, the patient population was heterogeneous,
patients were treated according to a variety of protocols with
different treatment strategies, and methods and timing of
follow-upwerenot standardized.Despite those limitations,we
believe this study gives a reliable estimate of the rate of AML
CNS involvement at time of HCT, identiﬁes risk factors for such
involvement, and evaluates its effect on transplant outcome.
Our results suggest that AML CNS disease pre-HCT is not
uncommon (7%), is primarily associated with a history of
prior CNS disease, and when treated is not an independent
factor in determining survival after HCT. Based on our ﬁnd-
ings and considering the relative low risk of lumbar punc-
ture, our recommendations are to perform routine CSF
evaluation in all AML patients before HCT, add imaging as
indicated based on clinical manifestation, and to treat any
CNS disease before transplant.ACKNOWLEDGMENTS
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